Shivaani Kummar, M.D., FACP, director of the Knight Cancer Institute and chief scientific and academic officer, Knight Cancer Group, is responsible for leading the institute's research, clinical and educational missions and overseeing the National Cancer Institute Cancer Center Support Grant and associated infrastructure. An internationally recognized physician-scientist and medical oncologist, her work focuses on early-phase cancer drug development and novel cancer therapeutics. In addition to serving as director of the OHSU Knight Cancer Institute, she is the Margaret and Lester DeArmond University chair of molecular oncology, and the co-director of the Center for Experimental Therapeutics.

Kummar earned her medical degree from Lady Hardinge Medical College in 1992, completed her residency in internal medicine at Emory University, and went on to a fellowship in medical oncology and hematology at the National Cancer Institute, part of the National Institutes of Health. 

Before joining OHSU in 2020, Kummar held faculty positions at Yale University and Stanford University, where she led innovative clinical research programs advancing new cancer therapies. Her research has helped shape the development of targeted therapies, immunotherapies and other innovative treatments for patients with cancer. A fellow of the American College of Physicians, Kummar is also a member of the National Cancer Policy Forum of the National Academies of Sciences, Engineering and Medicine.